Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
Alphamab seals $2.2 billion licensing deal with AI biotech
The Chinese drug firm has chosen to partner with an AI specialist rather than Big Pharma on a dual-target cancer therapy, netting an upfront payment of $125 million Key Takeaways:…
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
The Chinese biotech said the enrollment marks a key milestone for its advancing bile duct cancer treatment By Teri Yu Clinical-stage biotech firm TransThera Sciences (Nanjing) Inc. (2617.HK) said it…
BRIEF: Kelun-Biotech raises $250 million through share placement
Innovative cancer drug company Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) announced on Thursday it plans to sell 5.92 million shares through a placement, representing 2.54% of its enlarged share capital.…
CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
Recent Articles
RELATED ARTICLES
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG - Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Can a novel sleeping pill help Jingxin shed its generic label?
002020.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
